BTK and mantle cell lymphoma: SRX3305 is a single agent which simultaneously binds to the catalytic domains of BTK and PI3K and bromodomains of BRD4 and inhibits the critical signaling pathways known to be aberrantly activated in MCL, including BTK, PI3K–AKT–mTOR and MYC-BRD4.